Pharma and healthcare mutual funds have yielded impressive returns in 2024. The sector benefited from resilience amidst corrections in other sectors and steady growth in the domestic market. Experts suggest a cautious approach to investment due to current valuations. A phased allocation strategy of 10-15% is recommended, with potential for increasing allocation over time.
